Titan Pharmaceuticals (NASDAQ:TTNP) will present two posters on its buprenorphine implant, Probuphine, at the tenth American Conference of Pharmacometrics.
Probuphine is a subdermal implant that provides six-month maintenance treatment for opioid use disorder (OUD) in eligible patients.
The presentations will review computer modeling study results, based on data from the company’s Phase 3 clinical trials, assessing the population pharmacokinetic (PK) parameters, exposure-response profiles, and drug-drug interaction (DDI) potential during treatment with Probuphine.
“These results suggest that the PK profiles for Probuphine are highly predictable, and that the maximum clinical benefit of buprenorphine for the treatment of OUD can be achieved in eligible patients at relatively low blood concentration levels,” EVP and CSO, Dr. Kate DeVarney, said in a statement.
“Further, the potential for DDI on buprenorphine exposure from Probuphine is similar to that reported for other marketed buprenorphine formulations,” she added.